Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Publication year range
1.
Arq Bras Endocrinol Metabol ; 53(1): 24-30, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19347182

ABSTRACT

OBJECTIVES: To analyze glucocorticoid (GC) sensitivity using intravenous very low dose dexamethasone suppression test (IV-VLD-DST) in patients with rheumatoid arthritis (RA) and its correlation with glucocorticoid receptor alpha-isoform (GRalpha) gene expression. METHODS: We evaluated 20 healthy controls and 32 RA patients with Health Assessment Questionnaire (HAQ) and Disease Activity Score 28 joints (DAS) scores and IV-VLD-DST and GRalpha expression in mononuclear cells. RESULTS: Basal cortisol and the percentage of cortisol reduction after IV-VLD-DST were lower in RA patients than in controls, whereas GRalpha expression was similar among groups. In the RA group there was an inverse correlation between GRalpha expression and the percentage of cortisol suppression that was not observed in controls. There was a direct relationship between DAS and GRalpha expression. CONCLUSIONS: Mechanisms involved in GC resistance observed in patients with RA are possibly not at the level of GRalpha gene expression, since it was similar among groups and GRalpha increased with disease activity.


Subject(s)
Arthritis, Rheumatoid , Dexamethasone/pharmacology , Drug Resistance/physiology , Glucocorticoids/pharmacology , Receptors, Glucocorticoid , Adult , Analysis of Variance , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/genetics , Case-Control Studies , Female , Humans , Hydrocortisone/blood , Male , Receptors, Glucocorticoid/drug effects , Receptors, Glucocorticoid/genetics
2.
Arq. bras. endocrinol. metab ; 53(1): 24-30, fev. 2009. graf, tab
Article in English | LILACS | ID: lil-509862

ABSTRACT

OBJECTIVES: To analyze glucocorticoid (GC) sensitivity using intravenous very low dose dexamethasone suppression test (IV-VLD-DST) in patients with rheumatoid arthritis (RA) and its correlation with glucocorticoid receptor alpha-isoform (GRα) gene expression. METHODS: We evaluated 20 healthy controls and 32 RA patients with Health Assessment Questionnaire (HAQ) and Disease Activity Score 28 joints (DAS) scores and IV-VLD-DST and GRα expression in mononuclear cells. RESULTS: Basal cortisol and the percentage of cortisol reduction after IV-VLD-DST were lower in RA patients than in controls, whereas GRα expression was similar among groups. In the RA group there was an inverse correlation between GRα expression and the percentage of cortisol suppression that was not observed in controls. There was a direct relationship between DAS and GRα expression. CONCLUSIONS: Mechanisms involved in GC resistance observed in patients with RA are possibly not at the level of GRα gene expression, since it was similar among groups and GRα increased with disease activity.


OBJETIVOS: Determinar a sensibilidade aos glicocorticóides (GC) utilizando teste de supressão com dexametasona em doses muito baixas (IV-VLD-DST) em pacientes com artrite reumatóide (AR) e sua correlação com a expressão gênica da isoforma alfa do receptor glicocorticóide (GRα). MÉTODOS: Foram avaliados 20 controles saudáveis e 32 pacientes com AR com Health Assessment Questionnaire (HAQ) e Disease Activity Score 28 joints (DAS), IV-VLD-DST e expressão do GRα em células mononucleares. RESULTADOS: Cortisol basal e porcentagem de redução do cortisol após IV-VLD-DST foram menores no grupo AR do que nos controles, enquanto a expressão de GRα foi similar entre eles. No grupo com AR, ocorreu correlação negativa entre a expressão do GRα e a porcentagem de supressão do cortisol, enquanto nos controles não houve correlação. Ocorreu relação direta entre DAS e expressão de GRα . CONCLUSÕES: Sugerimos que os mecanismos envolvidos na resistência aos GC observada na AR não estejam ao nível da expressão gênica do GRα, já que esta é igual entre os grupos e aumenta com a gravidade da doença.


Subject(s)
Adult , Female , Humans , Male , Arthritis, Rheumatoid , Dexamethasone/pharmacology , Drug Resistance/physiology , Glucocorticoids/pharmacology , Receptors, Glucocorticoid , Analysis of Variance , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/genetics , Case-Control Studies , Hydrocortisone/blood , Receptors, Glucocorticoid/drug effects , Receptors, Glucocorticoid/genetics
3.
Arq Bras Endocrinol Metabol ; 52(1): 101-8, 2008 Feb.
Article in Portuguese | MEDLINE | ID: mdl-18345402

ABSTRACT

Hydrocortisone acetate is usually employed in the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. In Brazil, however, oral hydrocortisone acetate is only available from manipulation pharmacies. Prednisolone has stable oral pharmaceutical formulations commercially available, with the advantage of a single daily dose. The aim of this study was to compare the efficacy of oral prednisolone and oral hydrocortisone in the treatment of CAH due to 21-hydroxylase deficiency. Fifteen patients with mean (SD) chronological age of 7.2 (3.6) years, were evaluated in two consecutive 1-year periods. In the first year, hydrocortisone (17.5 mg/m2/day, divided in three doses) was used in the treatment, followed by the use of prednisolone (3 mg/m2/day, once in the morning) in the second year. The comparison between the two treatments was assessed after a one-year treatment period by: variation of height standard deviation score (SDS) (delta Height SDS), variation of height SDS according to bone age (delta BA SDS), variation of body mass SDS (delta BMI SDS) and serum levels of androstenedione. No significant difference was observed in relation to the delta Height SDS, delta BA SDS and delta BMI SDS. No significant difference was observed in the serum levels of androstenedione. We conclude that the efficacy of prednisolone administered once a day orally is comparable to the oral use of hydrocortisone three times a day. Oral prednisolone may be an option for patients with CAH due to 21-hydroxylase deficiency.


Subject(s)
Adrenal Hyperplasia, Congenital/drug therapy , Anti-Inflammatory Agents/therapeutic use , Glucocorticoids/therapeutic use , Prednisolone/therapeutic use , Steroid 21-Hydroxylase/metabolism , Adolescent , Anti-Inflammatory Agents/administration & dosage , Body Height , Body Mass Index , Child , Child, Preschool , Female , Glucocorticoids/administration & dosage , Humans , Infant , Male , Prednisolone/administration & dosage
4.
Arq. bras. endocrinol. metab ; 50(6): 983-995, dez. 2006. ilus
Article in Portuguese, English | LILACS | ID: lil-439716

ABSTRACT

Os glicocorticóides exercem um papel importante na regulação fisiológica e na adaptação a situações de stress, sendo a maioria dos efeitos destes hormônios mediada pela interação com os receptores glicocorticóides. A sensibilidade ao glicocorticóide depende da densidade celular de receptores expressos, bem como da eficiência da transdução do sinal mediada pelo complexo hormônio-receptor. Os estados de resistência ou de hipersensibilidade ao glicocorticóide, observados, respectivamente, nas doenças inflamatórias auto-imunes e na síndrome metabólica, podem representar a variabilidade dos fatores que influenciam a cascata de sinalização do glicocorticóide. O reconhecimento destes fatores contribui para uma melhor compreensão tanto do fenótipo clínico e da evolução destas doenças quanto da resposta terapêutica com glicocorticóide. A compreensão destes mecanismos fisiopatológicos também pode contribuir para a escolha de intervenções terapêuticas. Neste artigo de revisão, descrevemos os múltiplos fatores envolvidos nesta cascata de sinalização, os quais são capazes de influenciar a sensibilidade ao glicocorticóide.


Glucocorticoids play an essential role in maintaining basal and stress-related homeostasis. Most known effects of glucocorticoids are mediated by the intracellular glucocorticoid receptors. The glucocorticoid sensitivity seems to depend on the amount of receptors expressed and the efficiency of glucocorticoid receptor-mediated signal transduction. Glucocorticoid resistance or hypersensitivity, seen in autoimmune-inflammatory diseases and in metabolic syndrome respectively, can represent the variability of several steps that influence the signaling cascade of glucocorticoid action. The recognition of these steps could provide the understanding of the clinical phenotype and course of such diseases as well as their responsiveness to glucocorticoid therapy. The comprehension of these pathophysiological mechanisms can also improve the possible therapeutic interventions. In this review, we have summarized the multiple factors that have been shown to be involved in this signaling cascade and, thus, to influence glucocorticoid sensitivity.


Subject(s)
Humans , Autoimmune Diseases/physiopathology , Glucocorticoids/physiology , Hypersensitivity/physiopathology , Metabolic Syndrome/physiopathology , Receptors, Glucocorticoid/physiology , Signal Transduction/physiology , Anti-Inflammatory Agents/pharmacology , Cell Proliferation/drug effects , Dexamethasone/pharmacology , Glucocorticoids/metabolism , Glucocorticoids/therapeutic use , Hypersensitivity/metabolism , Inflammation/physiopathology , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , Signal Transduction/drug effects
5.
Arq Bras Endocrinol Metabol ; 50(6): 983-95, 2006 Dec.
Article in Portuguese | MEDLINE | ID: mdl-17221103

ABSTRACT

Glucocorticoids play an essential role in maintaining basal and stress-related homeostasis. Most known effects of glucocorticoids are mediated by the intracellular glucocorticoid receptors. The glucocorticoid sensitivity seems to depend on the amount of receptors expressed and the efficiency of glucocorticoid receptor-mediated signal transduction. Glucocorticoid resistance or hypersensitivity, seen in autoimmune-inflammatory diseases and in metabolic syndrome respectively, can represent the variability of several steps that influence the signaling cascade of glucocorticoid action. The recognition of these steps could provide the understanding of the clinical phenotype and course of such diseases as well as their responsiveness to glucocorticoid therapy. The comprehension of these pathophysiological mechanisms can also improve the possible therapeutic interventions. In this review, we have summarized the multiple factors that have been shown to be involved in this signaling cascade and, thus, to influence glucocorticoid sensitivity.


Subject(s)
Autoimmune Diseases/physiopathology , Drug Hypersensitivity/physiopathology , Glucocorticoids/physiology , Metabolic Syndrome/physiopathology , Receptors, Glucocorticoid/physiology , Signal Transduction/physiology , Anti-Inflammatory Agents/pharmacology , Cell Proliferation/drug effects , Dexamethasone/pharmacology , Drug Resistance , Glucocorticoids/metabolism , Glucocorticoids/therapeutic use , Humans , Inflammation/physiopathology , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , Signal Transduction/drug effects
6.
Arq. bras. endocrinol. metab ; 49(3): 378-383, jun. 2005. tab, graf
Article in English | LILACS | ID: lil-409844

ABSTRACT

As potências antiinflamatória e imunossupressora dos glicocorticóides (GC) já foram bem estabelecidas previamente. No entanto, os GC também possuem atividade reguladora da proliferação celular e da morte celular programada (apoptose). O objetivo deste estudo foi determinar a potência relativa de diferentes GC na modulação da sobrevida celular. Linfoblastos cortico-sensíveis (linhagem celular CEM-C7/14) foram mantidos em cultura prolongada e submetidos ao tratamento com GC por 48h, em doses variando entre 10-8 e 10-5 molar. O índice de sobrevida celular foi quantificado pelo teste MTT (DimetilTiazol-Tetrezolium). Para cada GC avaliado, foram realizados pelo menos quatro experimentos em quadruplicata. A resposta celular aos diferentes GC foi analisada através do teste estatístico ANOVA on Ranks, enquanto a resposta ao mesmo GC em concentrações diferentes foi analisada pelo teste ANOVA for repeated measures. O EC50 de cada GC foi calculado utilizando-se o software GraphPad Prism 3.0. Durante o uso de concentrações baixas (10-8 e 10-7 molar), observou-se sobrevida semelhante dos linfoblastos após tratamento com hidrocortisona ou metilprednisolona. Nestas mesmas concentrações baixas, a sobrevida celular foi menor quando utilizou-se dexametasona, betametasona, budesonida ou mometasona. A mometasona e a metilprednisolona foram os dois GC que determinaram maior redução da sobrevida linfoblástica. Nossos resultados sugerem que as potências antiproliferativa e pró-apoptótica dos GC sejam diferentes dos efeitos antiinflamatórios e imunossupressores previamente estabelecidos para estes GC.


Subject(s)
Humans , Anti-Inflammatory Agents/pharmacology , Apoptosis/drug effects , Cell Proliferation/drug effects , Glucocorticoids/pharmacology , Immunosuppressive Agents/pharmacology , Analysis of Variance , Cell Survival/drug effects , Gene Expression Regulation
7.
Arq Bras Endocrinol Metabol ; 49(3): 378-83, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16543991

ABSTRACT

Relative antiinflammatory and immunosuppressive potencies of glucocorticoids (GC) were previously well defined. Nonetheless, GC also regulate cell proliferation and programmed death (apoptosis). The aim of this study was to determine the relative potency of different GC on the modulation of cell survival. The GC-sensitive lymphoblast cell line CEM-c7/14 was submitted to 48 h-exposure to GC (dose-response curve from 10(-8) to 10(-5) M). Cell survival was analyzed employing the DimethylTiazol-Tetrazolium (MTT) test. For each GC at least 4 experiments were performed in quadruplicate. Responses to different GC at the same molarity were analyzed by ANOVA on Ranks. Cell responses to the same GC in different concentrations were tested by repeated measures ANOVA. The EC50 for each GC was calculated with the GraphPad Prism 3.0 software. The use of low concentrations (10(-8) and 10(-7) M) of hydrocortisone and methylprednisolone determined a similar effects on cell survival, which was less prominent than that observed with betamethasone, budesonide or momethasone. Momethasone was the most potent GC, inducing the most intense dexamethasone reduction on cell survival at the lowest concentration (10(-8) M). Momethasone and methylprednisolone were the two GC with the strongest impact on cell survival. Our findings suggest that antiproliferative and apoptotic potencies of GC are different from those previously reported antiinflammatory and immunosuppressive actions.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Apoptosis/drug effects , Cell Proliferation/drug effects , Glucocorticoids/pharmacology , Immunosuppressive Agents/pharmacology , Analysis of Variance , Cell Line , Cell Survival/drug effects , Gene Expression Regulation , Humans
8.
BMC Mol Biol ; 5(1): 19, 2004 Oct 26.
Article in English | MEDLINE | ID: mdl-15507144

ABSTRACT

BACKGROUND: The expression of glucocorticoid-receptor (GR) seems to be a key mechanism in the regulation of glucocorticoid (GC) sensitivity and is potentially involved in cases of GC resistance or hypersensitivity. The aim of this study is to describe a method for quantitation of GR alpha isoform (GRalpha) expression using real-time PCR (qrt-PCR) with analytical capabilities to monitor patients, offering standard-curve reproducibility as well as intra- and inter-assay precision. RESULTS: Standard-curves were constructed by employing standardized Jurkat cell culture procedures, both for GRalpha and BCR (breakpoint cluster region), as a normalizing gene. We evaluated standard-curves using five different sets of cell culture passages, RNA extraction, reverse transcription, and qrt-PCR quantification. Intra-assay precision was evaluated using 12 replicates of each gene, for 2 patients, in a single experiment. Inter-assay precision was evaluated on 8 experiments, using duplicate tests of each gene for two patients. Standard-curves were reproducible, with CV (coefficient of variation) of less than 11%, and Pearson correlation coefficients above 0,990 for most comparisons. Intra-assay and inter-assay were 2% and 7%, respectively. CONCLUSION: This is the first method for quantitation of GRalpha expression with technical characteristics that permit patient monitoring, in a fast, simple and robust way.


Subject(s)
Polymerase Chain Reaction/methods , Receptors, Glucocorticoid/genetics , Adult , Child , Female , Humans , Jurkat Cells , Male , Polymerase Chain Reaction/standards , RNA, Messenger/analysis , RNA, Messenger/metabolism , Receptors, Glucocorticoid/biosynthesis , Reference Standards , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...